ストックスクリーナーアプリを入手
2.56
6.57%
-0.18
アフターアワーズ：
2.56
Orchestra Biomed Holdings Inc (OBIO) 最新ニュース
Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Finance
OBIO: Riding the Market Waves of Growth and Decline in 2023 - investchronicle.com
How did Orchestra BioMed Holdings Inc (OBIO) fare last session? - uspostnews.com
Orchestra BioMed Secures FDA Clearance for Virtue Trial to Advance Coronary ISR Treatment - MyChesCo
Orchestra Biomed sees $149,201 stock purchase by RTW Investments By Investing.com - Investing.com Australia
Orchestra BioMed Holdings Inc [OBIO] Records 200-Day SMA of $5.25 - knoxdaily.com
Orchestra BioMed to Present at Jefferies Global Healthcare Conference - MyChesCo
Geode Capital Management LLC Boosts Stock Holdings in Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) - Defense World
FDA approves head-to-head trial of Orchestra BioMed’s balloon - Investing.com
Orchestra BioMed Receives FDA Breakthrough Device Designation for AVIM Therapy - Diagnostic and Interventional Cardiology
FDA Clears Orchestra BioMed's Virtue SAB Trial To Treat Coronary ISR - Nasdaq
Orchestra BioMed (OBIO) Gains FDA Nod for Updated Coronary ISR T - GuruFocus
Orchestra BioMed Receives FDA Approval for IDE Amendment - TipRanks
Orchestra Biomed Receives FDA Approval Of Ide To Initiate U.S. Coronary Pivotal Trial Randomizing First-In-Class Sirolimus-Angioinfusion Balloon, Virtue Sab, Head-To-Head With Paclitaxel-Coated Balloon - marketscreener.com
Orchestra BioMed Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-AngioInfusion Balloon, Virtue SAB, Head-to-Head with Paclitaxel-Coated Balloon - GlobeNewswire
Orchestra BioMed's Revolutionary Sirolimus Balloon Gets FDA Green Light for Head-to-Head Trial - Stock Titan
Orchestra BioMed (NASDAQ:OBIO) Shares Down 6.1% – Time to Sell? - Defense World
Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences - GlobeNewswire
Orchestra BioMed Secures Triple Conference Lineup: CEO Sets Major Investor Presentations - Stock Titan
Analyzing PetVivo (NASDAQ:PETV) & Orchestra BioMed (NASDAQ:OBIO) - Defense World
Orchestra BioMed to Highlight Advancements in Cardiac Therapy at HRS 2025 - MSN
Orchestra BioMed stock holds Buy rating, $12 target from H.C. Wainwright - Investing.com Canada
Financial Metrics Unveiled: Orchestra BioMed Holdings Inc (OBIO)’s Key Ratios in the Spotlight - DWinneX
Orchestra BioMed Secures FDA Breakthrough Device Designation for AVIM Therapy - MSN
When (OBIO) Moves Investors should Listen - news.stocktradersdaily.com
Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting - Investing News Network
Orchestra BioMed Hosts Symposium on Breakthrough AVIM Therapy for Uncontrolled Hypertension at HRS 2025 Annual Meeting - Nasdaq
FDA Breakthrough Therapy for 7.7M Hypertension Patients: New Clinical Data | OBIO Stock News - Stock Titan
Examining the Potential Price Growth of Orchestra BioMed Holdings Inc (OBIO) - knoxdaily.com
Investors Take Advantage Of 0.70% Gain In Orchestra BioMed Holdings Inc (NASDAQ: OBIO) - Stocksregister
FDA grants breakthrough status to Orchestra BioMed’s AVIM therapy By Investing.com - Investing.com Canada
Orchestra BioMed Holdings Inc: A Year of Highs, Lows, and Market Resilience - investchronicle.com
There Are Mixed Signals on the Chart for Orchestra BioMed Holdings Inc (OBIO) - uspostnews.com
FDA grants breakthrough status to Orchestra BioMed’s AVIM therapy - Investing.com Australia
Orchestra BioMed shares surge on FDA breakthrough designation By Investing.com - Investing.com Nigeria
Orchestra BioMed (OBIO) Gains FDA Breakthrough Device Status for AVIM Therapy | OBIO Stock News - GuruFocus
Orchestra BioMed shares surge on FDA breakthrough designation - Investing.com Australia
Orchestra BioMed Receives FDA Breakthrough Device Designation for Atrioventricular Interval Modulation Therapy to Address Uncontrolled Hypertension - Nasdaq
Orchestra BioMed (OBIO) Receives FDA Breakthrough Device Designation for AVIM Therapy - StreetInsider
Orchestra's Revolutionary Blood Pressure Device Earns FDA Breakthrough Status: 7.7M Patients Could Benefit - Stock Titan
Orchestra BioMed Reports 2024 Financial Results and Advances Cardiovascular Therapy - MSN
0.39%
3.66%
大文字化:
|
ボリューム (24 時間):